Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2024-02-28 00:00:00 ET · period of report 2024-02-26 · accession 0000950170-24-022413 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-28 | 2024-02-26 | AMLX | Cohen Joshua B | Co-CEO, Dir | A - Grant | $0.00 | +126.7K | 3.03M | +4% | $0 |
| D | 2024-02-28 | 2024-02-26 | AMLX | Cohen Joshua B | Co-CEO, Dir | A - Grant | $0.00 | +190.0K | 190.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-26 | A | A | 126,667 | $0.00 | 3,027,137 | D | — | — | (F1) The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2024-02-26 | A | A | 190,000 | $0.00 | 190,000 | D | $17.56 · — to 2034-02-25 | 190,000 Common Stock | (F2) 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |